Health In Tech, Inc. Class A AI Stock Analysis
Want to see HIT full AI Analyst Report?
Health In Tech, Inc. Class A (HIT) AI Stock Analysis
Health In Tech, Inc. Class A
(NASDAQ:HIT)
The score is held down primarily by sharply weaker financial performance (large losses, margin compression, and negative operating/free cash flow) and bearish technicals (price below all major moving averages with negative MACD). Earnings-call messaging provides some offset via revenue outlook, pipeline, and improving cash usage, but execution risks (conversion rates, delays, and limited 2027 visibility) remain high; valuation support is limited by a negative P/E and no dividend.
Health In Tech, Inc. Class A (HIT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $21.20M
- Dividend Yield
- ―
- Average Volume (3M)
- 173.57K
- Price to Earnings (P/E)
- -2.1
- Beta (1Y)
- 1.29
- Revenue Growth
- 0.65%
- EPS Growth
- -814.29%
- Country
- US
- Employees
- 89
- Sector
- General
- Sector Strength
- 55
- Industry
- Software - Application
Health In Tech, Inc. Class A Business Overview & Revenue Model
Company Description
Health In Tech, Inc. operates as a cutting-edge insurance technology provider. The company delivers a range of specialized insurance solutions for smaller enterprises, such as value-based pricing strategies, group insurance captives, localized commun...
Health In Tech, Inc. Class A Earnings Call Summary
The call presented a mixed, transitional outlook. Health In Tech highlighted a growing distribution network, substantial pipeline and contracted-revenue visibility, improving operating cash flow, a stronger cash position and multiple product initiatives targeted for commercialization. However, these positives were offset by declining reported revenue, gross-margin compression, significant credit-loss provisions, negative EBITDA and net losses, delayed commercialization, low historical pipeline conversion and the absence of finalized 2027 guidance. Management expressed confidence in the opportunity but acknowledged that execution and conversion remain the central challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Health In Tech updated its full year 2026 revenue outlook to approximately $30 million and said gross margin would maintain in the range of 45% to 50% in the coming quarters; its $153.8 million pipeline carries an expected conversion rate of 3% to 7%, meaning it would generate $9.3 million to $10.7 million revenue for the 3 months, while approximately 70% of the approximately $150 million potential annualized revenue pipeline was associated with January 1, 2027. The company’s goal is to complete the first end-to-end Three-Year Rate Stabilization Program launch by the end of 2026, launch the HitRix minimum viable product in the first quarter of 2027, and launch an initial HITChain minimum viable product during the second half of 2027; management said HitRix is probably Q2 opportunity at the earliest, HITChain is a second half 2027 opportunity, and expected further improvement in operating cash flow as it commercializes the new service and product in 2027, but it is not presenting a finalized 2027 plan or revenue outlook today.
Health In Tech, Inc. Class A Financial Statement Overview
Summary
Operating results and cash generation deteriorated sharply: TTM swung to a large net loss (net margin ~-37%) with notable gross-margin compression, and operating/free cash flow turned negative (OCF ~-$6.8M; FCF ~-$7.6M). The main offset is a conservatively levered balance sheet (very low debt-to-equity), but losses and cash burn are the dominant near-term risk.
Income Statement
34NegativeBalance Sheet
73PositiveCash Flow
29Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 30.92M | 33.33M | 19.49M | 19.15M | 5.77M |
| Gross Profit | 15.90M | 20.94M | 15.44M | 16.85M | 5.44M |
| EBITDA | -13.26M | 2.57M | 1.93M | 3.76M | 205.58K |
| Net Income | -11.47M | 1.28M | 670.48K | 2.48M | 79.74K |
Balance Sheet | |||||
| Total Assets | 28.03M | 23.09M | 15.77M | 11.50M | 28.56M |
| Cash, Cash Equivalents and Short-Term Investments | 10.13M | 7.67M | 7.85M | 2.42M | 1.49M |
| Total Debt | 6.72M | 139.81K | 206.69K | 1.92M | 316.09K |
| Total Liabilities | 16.89M | 5.98M | 2.60M | 5.41M | 27.14M |
| Stockholders Equity | 12.85M | 17.11M | 13.17M | 6.09M | 1.05M |
Cash Flow | |||||
| Free Cash Flow | -7.57M | -56.11K | 1.28M | 384.52K | -436.63K |
| Operating Cash Flow | -6.83M | 3.13M | 2.18M | 1.53M | 782.75K |
| Investing Cash Flow | -2.57M | -3.13M | -836.75K | -1.94M | -1.22M |
| Financing Cash Flow | 11.50M | -187.39K | 4.09M | 1.34M | 1.88M |
Health In Tech, Inc. Class A Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HIT, the sentiment is Negative. The current price of 0.40 is below the 20-day moving average (MA) of 0.57, below the 50-day MA of 0.72, and below the 200-day MA of 1.11, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 26.85 is Positive, neither overbought nor oversold. The STOCH value of 28.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HIT.
Health In Tech, Inc. Class A Risk Analysis
Health In Tech, Inc. Class A disclosed 39 risk factors in its most recent earnings report. Health In Tech, Inc. Class A reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
2 New RisksHealth In Tech, Inc. Class A Peers Comparison
Overall Rating
WFCF71Outperform
RSSS68Neutral
SSTI49Neutral
HIT43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 71Outperform | $80.84M | 70.81 | 12.28% | ― | -0.66% | -55.74% | |
| 68Neutral | $67.86M | 22.53 | 15.55% | ― | -1.53% | 140.44% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 49Neutral | $109.37M | -4.67 | -34.73% | ― | -4.75% | -108.66% | |
| 43Neutral | $25.83M | -2.13 | -64.51% | ― | 0.65% | -814.29% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HIT | Health In Tech, Inc. Class A | 0.40 | -0.98 | -71.38% | |
| WFCF | Where Food Comes From, Inc. | 16.30 | 4.61 | 39.44% | |
| SSTI | Soundthinking, Inc. | 8.26 | 2.13 | 34.75% | |
| RSSS | Research Solutions | 2.01 | -0.79 | -28.21% |
Health In Tech, Inc. Class A Corporate Events
Health In Tech Reports Third-Quarter Revenue and Losses
NegativeOn November 12, 2026, Health In Tech reported unaudited third-quarter revenue of $6.6 million, down from $8.5 million a year earlier, while nine-month revenue was $23.4 million versus $25.8 million. Distribution partners reached 984 as of September 3...
Health In Tech Discusses Q3 Results and Leadership Changes
NegativeOn Nov. 12, 2026, Health In Tech hosted a conference call covering its operating and financial results for the quarter ended Sept. 30, 2026. Executives said the company had invested during 2026 in its sales and distribution network, industry relation...
Health In Tech Details AI-Enabled Marketplace in Investor Presentation
PositiveOn November 12, 2026, Health In Tech prepared an investor presentation for use by company officers and representatives at conferences and meetings. The presentation described an AI-enabled marketplace for self-funded health plans and cited bindable q...
Health In Tech Holds Annual Meeting, Approves Key Proposals
NeutralOn November 10, 2026, Health In Tech held its annual meeting, where stockholders elected five director nominees, including new nominee Tim Cortes, to serve until the 2027 annual meeting or until their successors were elected and qualified.Stockholder...
Health In Tech Completes Second Prepaid Advance Closing
NeutralOn November 2, 2026, Health In Tech, Inc. completed its second pre-paid advance closing with YA II PN, Ltd., issuing a $3.0 million promissory note at a 5% purchase-price discount and receiving $2.85 million in gross proceeds. The related Form S-3 re...
Health In Tech Names Sanjay Shrestha as New CEO
PositiveOn October 20, 2026, Health In Tech appointed former Plug Power president and seasoned capital markets executive Sanjay Shrestha as Chief Executive Officer, while founder Tim Johnson moved into the role of Executive Chairman to concentrate on long-te...
Health In Tech Faces Nasdaq Listing Compliance Challenges
NegativeOn October 14, 2026, Health In Tech disclosed that Nasdaq has determined the company is out of compliance with independent director and audit committee rules following the August 10, 2026 resignation of director Sanjay Shrestha, leaving its four-memb...
Health In Tech Launches HitRix AI Insurance Platform
NeutralOn September 30, 2026, Health In Tech launched HitRix, an AI-powered platform designed to modernize the nearly $1 trillion U.S. self-funded health insurance market by streamlining large-group submissions and multi-market quoting in a single secure en...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
